$10.10 Million in Sales Expected for Cellectis SA (CLLS) This Quarter

Brokerages forecast that Cellectis SA (NASDAQ:CLLS) will post sales of $10.10 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Cellectis’ earnings, with the lowest sales estimate coming in at $9.00 million and the highest estimate coming in at $11.31 million. Cellectis posted sales of $13.02 million in the same quarter last year, which suggests a negative year over year growth rate of 22.4%. The business is expected to report its next quarterly earnings report on Monday, March 5th.

According to Zacks, analysts expect that Cellectis will report full year sales of $10.10 million for the current financial year, with estimates ranging from $34.00 million to $39.85 million. For the next year, analysts expect that the business will post sales of $40.21 million per share, with estimates ranging from $33.00 million to $45.22 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Cellectis.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, November 13th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.16). Cellectis had a negative net margin of 217.25% and a negative return on equity of 30.66%.

A number of analysts have recently weighed in on CLLS shares. Zacks Investment Research lowered Cellectis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 17th. Jefferies Group reaffirmed a “buy” rating and set a $47.00 price objective on shares of Cellectis in a research report on Sunday, October 29th. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Cellectis in a research report on Thursday, December 28th. SunTrust Banks reaffirmed a “hold” rating and set a $20.00 price objective on shares of Cellectis in a research report on Friday, October 6th. Finally, BidaskClub raised Cellectis from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $39.29.

Shares of Cellectis (CLLS) opened at $29.48 on Friday. Cellectis has a 12-month low of $17.29 and a 12-month high of $35.07.

Institutional investors have recently bought and sold shares of the company. ARK Investment Management LLC increased its position in shares of Cellectis by 79.1% during the second quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 1,784 shares during the period. Williams Jones & Associates LLC purchased a new stake in shares of Cellectis during the second quarter worth $244,000. Wells Fargo & Company MN increased its position in shares of Cellectis by 132.1% during the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after acquiring an additional 5,435 shares during the period. KBC Group NV purchased a new stake in shares of Cellectis during the third quarter worth $366,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Cellectis during the third quarter worth $517,000. 16.35% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/21/10-10-million-in-sales-expected-for-cellectis-sa-clls-this-quarter.html.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply